Antigen
Anything an antibody or immune cell can recognise, typically a protein on a cell's surface. In cancer, an antigen is the flag that tells a drug or an immune cell 'this is the cell to attack'.
Most cancer antigens are ordinary human proteins that a tumour makes in unusual amounts (HER2, TROP2, CD19, PSMA), so drugs targeting them also touch normal cells that carry a little; truly tumour-specific antigens arise from mutations (neoantigens) or from viral proteins. A good drug antigen is abundant on tumour cells, scarce on essential normal tissue, and stable over time. Tumours escape by losing the antigen, which is how CD19-negative relapse defeats CAR-T, and by hiding the pieces of antigen they would normally display to T cells.
Pages like this
not linked directly; found by shared links- TermB cell
Shares Monoclonal, Immune system, Antibody, T cell.
- TermAntigen escape (antigen loss, lineage switch)
Shares BCMA, Drug resistance (primary and acquired), CD19, T-cell engagers (bispecific).
- TermImmunotherapy
Shares Immune system, T cell, Neoantigen, T-cell engagers (bispecific).
- TermNK cell
Shares Immune system, Antibody, T cell.
- TermLymphoma (tissue type)
Shares Antibody, T cell, CD19, T-cell engagers (bispecific).
- InstitutionUnion Hospital, Tongji Medical College
Shares BCMA, CD19, Antibody-drug conjugate (ADC), CAR-T cell therapy.
- TermCytokine
Shares Immune system, T cell, T-cell engagers (bispecific), CAR-T cell therapy.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares BCMA, CD19, CAR-T cell therapy.